샘플 요청 목록

 카트 문의
시장보고서
상품코드
1660885

세계의 요로감염(UTI) 치료 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Urinary Tract Infection (UTI) Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
발행일: | 리서치사: Persistence Market Research | 페이지 정보: 영문 189 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 요로감염(UTI) 치료 시장 규모는 2025년에 103억 7,000만 달러에 이르고, 2025-2032년의 예측 기간 동안 5.5%의 연평균 복합 성장률(CAGR)로 확대되어 2032년에는 150억 8,000만 달러에 달할 것으로 예상됩니다.

요로감염(UTI) 치료 시장에는 요로에 영향을 미치는 세균 및 곰팡이 감염을 관리하는 데 사용되는 의약품 치료가 포함됩니다. 일반적으로 방광, 요도, 신장에 영향을 미치는 이러한 감염은 전 세계적으로 광범위한 건강 문제입니다. 요로결석 유병률 증가, 항생제 내성 증가, 노인 인구 증가가 시장을 주도하고 있습니다. 새로운 항생제 및 대체 치료법에 대한 지속적인 연구가 시장 전망을 더욱 형성하고 있습니다.

비위생, 당뇨병과 같은 만성질환, 항균제 내성 증가로 인한 요로결석 발생률 증가 등 여러 요인이 세계 요로감염(UTI) 치료 시장의 성장에 기여하고 있습니다. 또한, 첨단 항생제 치료법과 프로바이오틱스 및 백신과 같은 비항생제 대체품의 개발이 시장 성장의 원동력이 되고 있습니다. 일반의약품(OTC)의 가용성과 요로결석의 조기 진단 및 치료에 대한 인식이 높아진 것도 시장 성장을 가속하고 있습니다.

요로감염(UTI) 치료 시장은 특히 약물 제제의 발전, 백신 개발, 조기 발견 및 조기 치료를 가능하게 하는 현장진단(Point-of-Care) 진단의 부상으로 큰 기회를 제공합니다. 신규 항균요법 및 식물요법(식물 유래 의약품)에 대한 투자는 새로운 수익원을 창출할 것으로 기대됩니다. 또한, 처방약에 쉽게 접근할 수 있는 원격의료와 온라인 약국의 도입이 증가하고 있는 것도 시장 접근성과 성장성을 높이고 있습니다.

세계의 요로감염(UTI) 치료 시장을 조사했으며, 약품 유형별, 용도별, 유통 채널별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

  • 시장 범위와 정의
  • 시장 역학
  • 거시경제 요인
  • COVID-19의 영향 분석
  • 예측 요인 - 관련성과 영향

제3장 부가가치 인사이트

제4장 세계의 요로감염(UTI) 치료 시장 전망

  • 주요 하이라이트
  • 시장 규모(10억 달러) 분석과 예측
  • 세계의 요로감염(UTI) 치료 시장 전망 : 약제 클래스별
  • 세계의 요로감염(UTI) 치료 시장 전망 : 용도별
  • 세계의 요로감염(UTI) 치료 시장 전망 : 유통 채널별

제5장 세계의 요로감염(UTI) 치료 시장 전망 : 지역별

  • 주요 하이라이트
  • 과거 시장 규모(10억 달러) 분석, 지역별, 2019년-2024년
  • 현재 시장 규모(10억 달러) 분석과 예측, 지역별, 2025년-2032년
    • 북미
    • 유럽
    • 동아시아
    • 남아시아 및 오세아니아
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장의 매력 분석 : 지역별

제6장 북미의 요로감염(UTI) 치료 시장 전망

제7장 유럽의 요로감염(UTI) 치료 시장 전망

제8장 동아시아의 요로감염(UTI) 치료 시장 전망

제9장 남아시아 및 오세아니아의 요로감염(UTI) 치료 시장 전망

제10장 라틴아메리카의 요로감염(UTI) 치료 시장 전망

제11장 중동 및 아프리카의 요로감염(UTI) 치료 시장 전망

제12장 경쟁 구도

  • 시장 점유율 분석, 2025년
  • 시장 구조
  • 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
    • Pfizer
    • Bayer AG
    • Almirall SA
    • GlaxoSmithKline Pharmaceuticals Ltd.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb
    • Shionogi & Co., Ltd
    • Cipla Inc.

제13장 부록

LSH 25.03.10

Persistence Market Research has recently released a comprehensive report on the global Urinary Tract Infection (UTI) Treatment Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Urinary Tract Infection (UTI) Treatment Market Size (2025E): USD 10.37 Bn
  • Projected Market Value (2032F): USD 15.08 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.5%

Urinary Tract Infection (UTI) Treatment Market - Report Scope:

The Urinary Tract Infection (UTI) Treatment Market encompasses pharmaceutical treatments used to manage bacterial and fungal infections affecting the urinary tract. These infections, which commonly impact the bladder, urethra, and kidneys, are a widespread global health concern. The market is driven by the rising prevalence of UTIs, increasing antibiotic resistance, and the growing geriatric population. Ongoing research in novel antibiotics and alternative treatment options is further shaping the market landscape.

Market Growth Drivers:

Several factors are contributing to the growth of the global UTI Treatment Market, including the increasing incidence of UTIs due to poor hygiene, chronic diseases like diabetes, and rising antimicrobial resistance. Additionally, the development of advanced antibiotic therapies and non-antibiotic alternatives such as probiotics and vaccines is driving market expansion. The availability of over-the-counter (OTC) medications and growing awareness about early diagnosis and treatment of UTIs are also fueling market growth.

Market Restraints:

Despite its positive growth trajectory, the UTI treatment market faces challenges, including the growing issue of antimicrobial resistance (AMR), which limits the effectiveness of conventional antibiotics. Strict regulatory frameworks and lengthy drug approval processes may also hinder market progress. Additionally, side effects associated with prolonged antibiotic use and the lack of awareness about UTI symptoms in certain regions pose hurdles to market expansion.

Market Opportunities:

The UTI Treatment Market presents significant opportunities, especially with advancements in drug formulations, vaccine development, and the rise of point-of-care diagnostics that enable early detection and treatment. Investment in novel antimicrobial therapies and phytotherapeutic treatments (plant-based medications) is expected to create new revenue streams. Additionally, the increasing adoption of telemedicine and online pharmacies for easy access to prescription drugs is enhancing market accessibility and growth potential.

Key Questions Answered in the Report:

  • What are the major factors driving growth in the UTI treatment market?
  • Which drug classes are expected to witness the highest demand?
  • How is antimicrobial resistance impacting the UTI treatment landscape?
  • Who are the leading players in the UTI treatment market, and what strategies are they adopting?
  • What are the emerging trends and future opportunities in the global UTI treatment market?

Competitive Intelligence and Business Strategy:

Leading pharmaceutical companies in the UTI Treatment Market, such as Pfizer, Bayer AG, and GlaxoSmithKline Pharmaceuticals Ltd., are focusing on drug innovation, strategic partnerships, and expanding their global distribution networks to maintain a competitive edge. These companies are also investing in clinical research and development of novel antibiotics and alternative therapies to combat antimicrobial resistance. Collaboration with healthcare providers and digital health platforms is another key strategy to enhance patient access to UTI medications and improve treatment outcomes.

Key Companies Profiled:

  • Pfizer
  • Bayer AG
  • Almirall SA
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb
  • Shionogi & Co., Ltd
  • Cipla Inc.

Urinary Tract Infection (UTI) Treatment Market Segmentation:

By Drug Class:

  • Penicillin and Combinations
  • Quinolones
  • Cephalosporins
  • Aminoglycoside Antibiotics
  • Sulphonamides (Sulfamethoxazole, Trimethoprim)
  • Azoles and Amphotericin B
  • Tetracycline (Doxycycline)
  • Nitrofurans (Nitrofurantoin)
  • Others

By Application:

  • Complicated Urinary Tract Infection
  • Uncomplicated Urinary Tract Infection

By Distribution Channel:

  • Hospital Pharmacies
  • Gynecology and Urology Clinics
  • Drug Stores
  • Retail Pharmacies
  • Online Drug Stores

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Urinary Tract Infection (UTI) Treatment Market Outlook
  • 1.2. Global Urinary Tract Infection (UTI) Treatment Market Outlook: Services
  • 1.3. Introduction/Key Findings
  • 1.4. Historical Market Size (US$ Bn) and Analysis, By Services, 2019 - 2024
  • 1.5. Current Market Size (US$ Bn) and Analysis and Forecast, By Services, 2025 - 2032
  • 1.6. Future Market Projections
  • 1.7. Premium Market Insights
  • 1.8. Industry Developments and Key Market Events
  • 1.9. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
  • 4.3. Global Urinary Tract Infection (UTI) Treatment Market Outlook: Drug Class
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019 - 2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
      • 4.3.3.1. Penicillin & Combinations
      • 4.3.3.2. Quinolones
      • 4.3.3.3. Cephalosporin
      • 4.3.3.4. Aminoglycoside Antibiotics
      • 4.3.3.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
      • 4.3.3.6. Azoles and Amphotericin B
      • 4.3.3.7. Tetracycline (Doxycycline)
      • 4.3.3.8. Nitrofurans (Nitrofurantoin)
      • 4.3.3.9. Others
    • 4.3.4. Market Attractiveness Analysis: Drug Class
  • 4.4. Global Urinary Tract Infection (UTI) Treatment Market Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
      • 4.4.3.1. Complicated Urinary Tract Infection
      • 4.4.3.2. Uncomplicated Urinary Tract Infection
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global Urinary Tract Infection (UTI) Treatment Market Outlook: Distribution Channel
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019 - 2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
      • 4.5.3.1. Hospital Pharmacies
      • 4.5.3.2. Gynecology and Urology Clinics
      • 4.5.3.3. Drug Stores
      • 4.5.3.4. Retail Pharmacies
      • 4.5.3.5. Online Drug Stores
    • 4.5.4. Market Attractiveness Analysis: Distribution Channel

5. Global Urinary Tract Infection (UTI) Treatment Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 6.2.1. By Country
    • 6.2.2. By Drug Class
    • 6.2.3. By Application
    • 6.2.4. By Distribution Channel
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 6.4.1. Penicillin & Combinations
    • 6.4.2. Quinolones
    • 6.4.3. Cephalosporin
    • 6.4.4. Aminoglycoside Antibiotics
    • 6.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 6.4.6. Azoles and Amphotericin B
    • 6.4.7. Tetracycline (Doxycycline)
    • 6.4.8. Nitrofurans (Nitrofurantoin)
    • 6.4.9. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 6.5.1. Complicated Urinary Tract Infection
    • 6.5.2. Uncomplicated Urinary Tract Infection
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Gynecology and Urology Clinics
    • 6.6.3. Drug Stores
    • 6.6.4. Retail Pharmacies
    • 6.6.5. Online Drug Stores
  • 6.7. Market Attractiveness Analysis

7. Europe Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 7.2.1. By Country
    • 7.2.2. By Drug Class
    • 7.2.3. By Application
    • 7.2.4. By Distribution Channel
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 7.4.1. Penicillin & Combinations
    • 7.4.2. Quinolones
    • 7.4.3. Cephalosporin
    • 7.4.4. Aminoglycoside Antibiotics
    • 7.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 7.4.6. Azoles and Amphotericin B
    • 7.4.7. Tetracycline (Doxycycline)
    • 7.4.8. Nitrofurans (Nitrofurantoin)
    • 7.4.9. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 7.5.1. Complicated Urinary Tract Infection
    • 7.5.2. Uncomplicated Urinary Tract Infection
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Gynecology and Urology Clinics
    • 7.6.3. Drug Stores
    • 7.6.4. Retail Pharmacies
    • 7.6.5. Online Drug Stores
  • 7.7. Market Attractiveness Analysis

8. East Asia Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 8.2.1. By Country
    • 8.2.2. By Drug Class
    • 8.2.3. By Application
    • 8.2.4. By Distribution Channel
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 8.4.1. Penicillin & Combinations
    • 8.4.2. Quinolones
    • 8.4.3. Cephalosporin
    • 8.4.4. Aminoglycoside Antibiotics
    • 8.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 8.4.6. Azoles and Amphotericin B
    • 8.4.7. Tetracycline (Doxycycline)
    • 8.4.8. Nitrofurans (Nitrofurantoin)
    • 8.4.9. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 8.5.1. Complicated Urinary Tract Infection
    • 8.5.2. Uncomplicated Urinary Tract Infection
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Gynecology and Urology Clinics
    • 8.6.3. Drug Stores
    • 8.6.4. Retail Pharmacies
    • 8.6.5. Online Drug Stores
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 9.2.1. By Country
    • 9.2.2. By Drug Class
    • 9.2.3. By Application
    • 9.2.4. By Distribution Channel
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 9.4.1. Penicillin & Combinations
    • 9.4.2. Quinolones
    • 9.4.3. Cephalosporin
    • 9.4.4. Aminoglycoside Antibiotics
    • 9.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 9.4.6. Azoles and Amphotericin B
    • 9.4.7. Tetracycline (Doxycycline)
    • 9.4.8. Nitrofurans (Nitrofurantoin)
    • 9.4.9. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 9.5.1. Complicated Urinary Tract Infection
    • 9.5.2. Uncomplicated Urinary Tract Infection
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Gynecology and Urology Clinics
    • 9.6.3. Drug Stores
    • 9.6.4. Retail Pharmacies
    • 9.6.5. Online Drug Stores
  • 9.7. Market Attractiveness Analysis

10. Latin America Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 10.2.1. By Country
    • 10.2.2. By Drug Class
    • 10.2.3. By Application
    • 10.2.4. By Distribution Channel
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 10.4.1. Penicillin & Combinations
    • 10.4.2. Quinolones
    • 10.4.3. Cephalosporin
    • 10.4.4. Aminoglycoside Antibiotics
    • 10.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 10.4.6. Azoles and Amphotericin B
    • 10.4.7. Tetracycline (Doxycycline)
    • 10.4.8. Nitrofurans (Nitrofurantoin)
    • 10.4.9. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 10.5.1. Complicated Urinary Tract Infection
    • 10.5.2. Uncomplicated Urinary Tract Infection
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Gynecology and Urology Clinics
    • 10.6.3. Drug Stores
    • 10.6.4. Retail Pharmacies
    • 10.6.5. Online Drug Stores
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 11.2.1. By Country
    • 11.2.2. By Drug Class
    • 11.2.3. By Application
    • 11.2.4. By Distribution Channel
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 11.4.1. Penicillin & Combinations
    • 11.4.2. Quinolones
    • 11.4.3. Cephalosporin
    • 11.4.4. Aminoglycoside Antibiotics
    • 11.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 11.4.6. Azoles and Amphotericin B
    • 11.4.7. Tetracycline (Doxycycline)
    • 11.4.8. Nitrofurans (Nitrofurantoin)
    • 11.4.9. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 11.5.1. Complicated Urinary Tract Infection
    • 11.5.2. Uncomplicated Urinary Tract Infection
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 11.6.1. Hospital Pharmacies
    • 11.6.2. Gynecology and Urology Clinics
    • 11.6.3. Drug Stores
    • 11.6.4. Retail Pharmacies
    • 11.6.5. Online Drug Stores
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Pfizer
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Bayer AG
    • 12.3.3. Almirall SA
    • 12.3.4. GlaxoSmithKline Pharmaceuticals Ltd.
    • 12.3.5. Merck & Co., Inc.
    • 12.3.6. Bristol-Myers Squibb
    • 12.3.7. Shionogi & Co., Ltd
    • 12.3.8. Cipla Inc.

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제